ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. (ACAD) Stock Overview
Explore ACADIA Pharmaceuticals Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
3.8B
P/E Ratio
10.03
EPS (TTM)
$2.21
ROE
0.36%
ACAD Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of ACADIA Pharmaceuticals Inc. (ACAD) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 50.17, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $27.90.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 10.03 and a market capitalization of 3.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.